Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

FXYD5 (FXYD domain containing ion transport regulator 5)

Written2008-07Setsuo Hirohashi
Pathology Division, National Cancer Center Research Institute 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

(Note : for Links provided by Atlas : click)

Identity

Other aliasDYSAD
Dysadherin
HSPC113
IWU-1
IWU1
KCT1
OIT2
PRO6241
RIC
UNQ2561
LocusID (NCBI) 53827
Atlas_Id 40652
Location 19q13.12  [Link to chromosome band 19q13]
Location_base_pair Starts at and ends at bp from pter
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
FXYD5 (19q13.12) / TSKU (11q13.5)GLMN (1p22.1) / FXYD5 (19q13.12)SFPQ (16q24.1) / FXYD5 (19q13.12)
SFPQ (1p34.3) / FXYD5 (19q13.12)TGFB1 (19q13.2) / FXYD5 (19q13.12)

DNA/RNA

Transcription 0.9 kb mRNA; 534 bp open reading frame.

Protein

 
  Dysadherin protein consists of 178 amino acids.
Description The deduced amino acid sequence consisted of two hydrophobic regions corresponding to a signal peptide and a transmembrane domain (146-162), a serine-, threonine-, and proline-rich extracellular domain, which is a target for O-glycosylation, anda short cytoplasmic region containing positively charged amino acid residues.
Expression Endothelial cell, T lymphocytes, basal cell of squamous epithelium.
Localisation Cell membrane
Homology The transmembrane domain of dysadherin and mouse RIC especially showed a very high degree of similarity to other ion channels such as Mat-8 chloride channel, phospholemman, which is the major plasma membrane substrate for cAMPdependent protein kinase and protein kinase C, and the subunit of Na, K-ATPase.

Implicated in

Note
  
Entity Various cancers
Disease Dysadherin, newly identified cell membrane glycoprotein, downregulates E-cadherin and promotes cancer invasion and metastasis. A reverse correlation between dysadherin expression and E-cadherin expression was observed in various cancers. Increased dysadherin expression was correlated with poor prognosis with head and neck squamous cell carcinoma, esophageal carcinoma, gastric carcinoma, colorectal carcinoma, melanoma and so on. Dysadherin expression in epitheloid sarcomas could be a used as powerful diagnostic marker for distinguishing epithelioid sarcomas from malignant rabdoid tumors.
  

Bibliography

Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S.
Br J Cancer. 2003; 88(5): 726-32.
PMID 12618882
 
In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.
Batistatou A, Peschos D, Tsanou H, Charalabopoulos A, Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K.
Br J Cancer. 2007; 96(9): 1404-8.
PMID 17437014
 
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis.
Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ.
Proc Natl Acad Sci U S A. 2007; 104(33): 13331-6.
PMID 17690250
 
Cell adhesion system and human cancer morphogenesis.
Hirohashi S, Kanai Y.
Cancer Sci. 2003; 94(7): 575-81. (Review)
PMID 12841864
 
Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis.
Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S.
Proc Natl Acad Sci USA. 2002; 99(1): 365-70.
PMID 11756660
 
Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Kawai A, Sonobe H, Takahira T, Kobayashi C, Yamamoto H, Tamiya S, Hirohashi S, Iwamoto Y, Tsuneyoshi M.
Am J Surg Pathol. 2007; 31(1): 85-94.
PMID 17197923
 
Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.
Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ, Nakanishi Y, Hirohashi S, Charalabopoulos K.
Am J Surg Pathol. 2006; 30(2): 185-93.
PMID 16434892
 
Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.
Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M, Hirohashi S.
Appl Immunohistochem Mol Morphol. 2004; 12(4): 323-8.
PMID 15536331
 
Dysadherin: a new player in cancer progression.
Nam JS, Hirohashi S, Wakefield LM.
Cancer Lett. 2007; 255(2): 161-9. (Review)
PMID 17442482
 
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM.
Cancer Res. 2006; 66(14): 7176-84.
PMID 16849564
 
Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S.
Cancer. 2005; 103(8): 1693-700.
PMID 15751018
 
Dysadherin: expression and clinical significance in thyroid carcinoma.
Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S.
J Clin Endocrinol Metab. 2003; 88(9): 4407-12.
PMID 12970317
 
Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto M, Hirohashi S, Imamura M.
Oncology. 2004; 67(1): 73-80.
PMID 15459499
 
Clinical significance of dysadherin expression in gastric cancer patients.
Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S, Imamura M.
Clin Cancer Res. 2004; 10(8): 2818-23.
PMID 15102690
 
Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells.
Shimamura T, Yasuda J, Ino Y, Gotoh M, Tsuchiya A, Nakajima A, Sakamoto M, Kanai Y, Hirohashi S.
Cancer Res. 2004; 64(19): 6989-95.
PMID 15466191
 
Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami K, Oda M, Watanabe G.
J Thorac Cardiovasc Surg. 2005; 130(3): 740-5.
PMID 16153922
 
Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
Tsuiji H, Takasaki S, Sakamoto M, Irimura T, Hirohashi S.
Glycobiology. 2003; 13(7): 521-7.
PMID 12672699
 
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.
Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z.
Pathol Oncol Res. 2004; 10(4): 212-8.
PMID 15619642
 
Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice.
Yanagihara K, Tanaka H, Takigahira M, Ino Y, Yamaguchi Y, Toge T, Sugano K, Hirohashi S.
Cancer Sci. 2004; 95(7): 575-82.
PMID 15245593
 

Citation

This paper should be referenced as such :
Hirohashi, S
FXYD5 (FXYD domain containing ion transport regulator 5)
Atlas Genet Cytogenet Oncol Haematol. 2009;13(6):413-414.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/FXYD5ID40652ch19q13.html


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
  TGFB1/FXYD5 (19q13)


External links

Nomenclature
Cards
AtlasFXYD5ID40652ch19q13.txt
Aliases
Genomic and cartography
Gene and transcription
RefSeq transcript (Entrez)
RefSeq genomic (Entrez)
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
BioGPS (Tissue expression)53827
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Protein Interaction databases
Ontologies - Pathways
Clinical trials, drugs, therapy
Miscellaneous
canSAR (ICR) (select the gene name)
Probes
Litterature
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Thu Oct 18 17:37:12 CEST 2018

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.